UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT
OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
April 1, 2011
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its
charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F [X] |
Form 40-F [ ] |
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] |
No [X] |
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____________________
Company Announcement
1 April 2011
Status regarding Novo Nordisk's holding of its own shares (31 March 2011)
In continuation of the company's announcement dated 2 February 2011 concerning a planned share repurchase programme, and pursuant to Section 204.25 of the New York Stock Exchange Listed Company Manual, this is to report that Novo Nordisk A/S (NYSE: NVO) and its wholly-owned affiliates on 31 March 2011 owned 29,453,509 of its own B shares of DKK 1, corresponding to a total nominal value of DKK 29,453,509 or 4.91% of the total share capital.
In the first quarter of 2011 a total of 2,196,500 B shares were repurchased, and 949,746 B shares were disposed of to employees in connection with employee incentive programmes.
Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 30,900 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.
Company Announcement no 20 / 2011 |
Page 1 of 2 |
|||
|
||||
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 Telefax: +45 4444 6626 |
Internet: novonordisk.com |
CVR Number: 24256790 |
For further information please contact: |
|
|
|
Media: |
Investors: |
|
|
Outside North America: Anne Margrethe Hauge Tel: (+45) 4442 3450 amhg@novonordisk.com |
Outside North America: Klaus Bülow Davidsen Tel: (+45) 4442 3176 klda@novonordisk.com |
|
|
|
Jannick Lindegaard Tel: (+45) 4442 4765 jlis@novonordisk.com |
|
|
In North America: Ken Inchausti Tel: (+1) 609 514 8316 kiau@novonordisk.com |
In North America: Hans Rommer Tel: (+1) 609 919 7937 hrmm@novonordisk.com |
Company Announcement no 20 / 2011 |
Page 2 of 2 |
|||
|
||||
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 Telefax: +45 4444 6626 |
Internet: novonordisk.com |
CVR Number: 24256790 |
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: April 1, 2011 |
NOVO NORDISK A/S Lars Rebien Sørensen, President and Chief Executive Officer |